UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Comparative Genomic Analysis and Physiological Properties of Limosilactobacillus fermentum SMFM2017-NK2 with Ability to Inflammatory Bowel Disease

Microorganisms (Basel), 2023-02, Vol.11 (3), p.547

2023

Volltextzugriff (PDF)

Operative fasting guidelines and postoperative feeding in paediatric anaesthesia-current concepts

Indian journal of anaesthesia, 2019-09, Vol.63 (9), p.707-712

2019

Volltextzugriff (PDF)

Incidence of post-procedure symptomatic urinary tract infection in children undergoing micturition cystourethrogram in the absence of antibiotic cover

The Gazette of the Egyptian Paediatric Association, 2022-05, Vol.70 (1), p.1-4, Article 15

2022

Volltextzugriff (PDF)

Comparative Genomic Analysis and Physiological Properties of ILimosilactobacillus fermentum/I SMFM2017-NK2 with Ability to Inflammatory Bowel Disease

Microorganisms (Basel), 2023-02, Vol.11 (3)

2023

Volltextzugriff (PDF)

Use of ultrasound to estimate the prevalence of occult spinal dysraphism in children undergoing urogenital and anorectal surgeries: A cross-sectional study

Journal of anaesthesiology, clinical pharmacology, 2024-01, Vol.40 (1), p.90-94

2024

Volltextzugriff (PDF)

Influence of early adalimumab serum levels on immunogenicity and long‐term outcome of anti‐TNF naive Crohn's disease patients: the usefulness of rapid testing

Alimentary pharmacology & therapeutics, 2018-10, Vol.48 (7), p.731-739

2018

Volltextzugriff (PDF)

Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases

Clinical gastroenterology and hepatology, 2018-12, Vol.16 (12), p.1937-1946.e8

2018

Volltextzugriff (PDF)

Validation of a Drug-Resistant Anti-Adalimumab Antibody Assay to Monitor Immunogenicity in the Presence of High Concentrations of Adalimumab

The AAPS journal, 2017-03, Vol.19 (2), p.468-474

2017

Volltextzugriff (PDF)

miR-339 Promotes Development of Stem Cell Leukemia/Lymphoma Syndrome via Downregulation of the BCL2L11 and BAX Proapoptotic Genes

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13), p.3522-3531

2018

Volltextzugriff (PDF)

Evaluating an easy sampling method using dried blood spots to determine vedolizumab concentrations

Journal of pharmaceutical and biomedical analysis, 2020-06, Vol.185, p.113224, Article 113224

2020

Volltextzugriff (PDF)

Development and validation of an optical biosensor for rapid monitoring of adalimumab in serum of patients with Crohn's disease

Drug testing and analysis, 2018-03, Vol.10 (3), p.592-596

2018

Volltextzugriff (PDF)

Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study

Journal of Crohn's and colitis, 2019-09, Vol.13 (10), p.1248-1256

2019

Volltextzugriff (PDF)

Antibodies Toward Vedolizumab Appear from the First Infusion Onward and Disappear Over Time

Inflammatory bowel diseases, 2017-12, Vol.23 (12), p.2202-2208

2017

Volltextzugriff (PDF)

Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assays

Journal of pharmaceutical and biomedical analysis, 2016-06, Vol.125, p.62-67

2016

Volltextzugriff (PDF)

Regulation of survivin by ErbB2 signaling : Therapeutic implications for ErbB2-overexpressing breast cancers

Cancer research (Chicago, Ill.), 2006-02, Vol.66 (3), p.1640-1647

2006

Volltextzugriff (PDF)

Sa1955 - Successful Dose De-Escalation to Adalimumab 40 mg Every Three Weeks in Patients with Crohn's Disease

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S406-S407

2017

Volltextzugriff (PDF)

346 - in Anti-TNF Naïve Crohn's Disease Patients Low Adalimumab Serum Levels at Week 4 Provoke Immunogenicity and Influence Therapy Outcome

Gastroenterology (New York, N.Y. 1943), 2018-05, Vol.154 (6), p.S-84-S-84

2018

Volltextzugriff (PDF)

Successful Dose De-Escalation to Adalimumab 40 mg Every Three Weeks in Patients with Crohn's Disease

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S406-S407

2017

Volltextzugriff (PDF)

Sa1883 - Antibodies Towards Vedolizumab Appear from Week 2 Onwards and Disappear upon Treatment

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S382-S382

2017

Volltextzugriff (PDF)

Antibodies Towards Vedolizumab Appear from Week 2 Onwards and Disappear upon Treatment

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S382-S382

2017

Volltextzugriff (PDF)

Oligogalacturonic acid and chitosan reduce stomatal aperture by inducing the evolution of reactive oxygen species from guard cells of tomato and Commelina communis

Plant physiology (Bethesda), 1999-09, Vol.121 (1), p.147-152

1999

Volltextzugriff (PDF)

Role of coblation in reducing pain and morbidity of adenoidectomy

International Journal of Otorhinolaryngology and Head and Neck Surgery, 2019-12, Vol.6 (1), p.123

2019

Volltextzugriff (PDF)

Immunoglobulin G4-Related Hypertrophic Pachymeningitis Presenting with Multiple Lower Cranial Nerve Palsies

Journal of Electrodiagnosis and Neuromuscular Diseases, 2023-12, Vol.25 (3), p.121-124

2023

Volltextzugriff (PDF)

Hemichorea associated with subcortical border-zone infarction and middle cerebral artery stenosis

Journal of Geriatric Neurology, 2022-03, Vol.1 (1), p.41-43

2022

Volltextzugriff (PDF)

Subacute Combined Degeneration Associated with Methylenetetrahydrofolate Reductase (MTHFR) C677T Polymorphism

Taehan Singyŏngkwa Hakhoe chi, 2021-11, Vol.39 (4), p.359-361

2021

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(26)

Sprache

Englisch
(26)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(15)
Science & Technology
(15)
Humans
(7)
Pharmacology & Pharmacy
(6)
Therapeutic Drug Monitoring
(5)
Adalimumab
(4)
Female
(4)
Gastroenterology & Hepatology
(4)
Chemistry
(3)
Chemistry, Analytical
(3)
Crohn's Disease
(3)
Immunogenicity
(3)
Inflammatory Bowel Diseases
(3)
Male
(3)
Pharmacokinetics
(3)
Physical Sciences
(3)
Adalimumab - Administration & Dosage
(2)
Adalimumab - Immunology
(2)
Adult
(2)
Animal Models
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Comparative Genomic Analysis and Physiological Properties of Limosilactobacillus fermentum SMFM2017-NK2 with Ability to Inflammatory Bowel Disease

Operative fasting guidelines and postoperative feeding in paediatric anaesthesia-current concepts

Incidence of post-procedure symptomatic urinary tract infection in children undergoing micturition cystourethrogram in the absence of antibiotic cover

Comparative Genomic Analysis and Physiological Properties of ILimosilactobacillus fermentum/I SMFM2017-NK2 with Ability to Inflammatory Bowel Disease

Use of ultrasound to estimate the prevalence of occult spinal dysraphism in children undergoing urogenital and anorectal surgeries: A cross-sectional study

Influence of early adalimumab serum levels on immunogenicity and long‐term outcome of anti‐TNF naive Crohn's disease patients: the usefulness of rapid testing

Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases

Validation of a Drug-Resistant Anti-Adalimumab Antibody Assay to Monitor Immunogenicity in the Presence of High Concentrations of Adalimumab

miR-339 Promotes Development of Stem Cell Leukemia/Lymphoma Syndrome via Downregulation of the BCL2L11 and BAX Proapoptotic Genes

Evaluating an easy sampling method using dried blood spots to determine vedolizumab concentrations

Development and validation of an optical biosensor for rapid monitoring of adalimumab in serum of patients with Crohn's disease

Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study

Antibodies Toward Vedolizumab Appear from the First Infusion Onward and Disappear Over Time

Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assays

Regulation of survivin by ErbB2 signaling : Therapeutic implications for ErbB2-overexpressing breast cancers

Sa1955 - Successful Dose De-Escalation to Adalimumab 40 mg Every Three Weeks in Patients with Crohn's Disease

346 - in Anti-TNF Naïve Crohn's Disease Patients Low Adalimumab Serum Levels at Week 4 Provoke Immunogenicity and Influence Therapy Outcome

Successful Dose De-Escalation to Adalimumab 40 mg Every Three Weeks in Patients with Crohn's Disease

Sa1883 - Antibodies Towards Vedolizumab Appear from Week 2 Onwards and Disappear upon Treatment

Antibodies Towards Vedolizumab Appear from Week 2 Onwards and Disappear upon Treatment

Oligogalacturonic acid and chitosan reduce stomatal aperture by inducing the evolution of reactive oxygen species from guard cells of tomato and Commelina communis

Role of coblation in reducing pain and morbidity of adenoidectomy

Immunoglobulin G4-Related Hypertrophic Pachymeningitis Presenting with Multiple Lower Cranial Nerve Palsies

Hemichorea associated with subcortical border-zone infarction and middle cerebral artery stenosis

Subacute Combined Degeneration Associated with Methylenetetrahydrofolate Reductase (MTHFR) C677T Polymorphism

Suchergebnisse filtern